Business

Circassia Pharmaceuticals will pay AIT Therapeutics $7.35 million up front plus potential milestone payments and royalties for the exclusive rights to commercialize AIT's AirNOvent ventilator compatible nitric oxide in the US and China, the company said. The company will issue ordinary shares to AIT to cover the upfront payment and anticipates doing the same for … [Read more...] about Circassia acquires US and Chinese rights to AIT’s AirNOvent inhaled nitric oxide

Ziccum, a spin out from Inhalation Sciences, has announced that it submitted a patent application for a temperature-stable dry powder formulation of adenovirus. According to the company, the formulation, which would be suitable for delivery by inhalation, can be held at over 40 °C for more than a week with no degradation. In July 2018, Ziccum announced that it had … [Read more...] about Ziccum submits patent application for dry powder adenovirus vaccine

MannKind Corporation has announced that it will offer Afrezza inhaled insulin directly to diabetes patients in the US and is also introducing a savings card program for US patients with commercial insurance . The direct purchase program is administered by Eagle Pharmacy. The first 1,000 patients to register for the direct purchase program will be eligible for … [Read more...] about MannKind announces low cost direct purchase program for Afrezza inhaled insulin

US-based StellaPharma has announced that it will acquire G2B Pharma (G2B) and its dry powder nasal formulation of epinephrine for the treatment of anaphylaxis. According to a 2014 press release, G2B had licensed SNBL's nasal delivery technology and was co-developing G2B011 epinephrine nasal spray with SNBL. Neither StellaPharma nor G2B appears to have a website … [Read more...] about StellaPharma acquires dry powder nasal epinephrine formulation

Glenmark Pharmaceuticals will receive an upfront payment, milestones, and royalties from Yuhan Corporation as part of a deal that gives Yuhan rights to commercialize Ryaltris olopatadine hydrochloride/mometasone furoate nasal spray for the treatment of seasonal allergic rhinitis in South Korea, Glenmark said. Specific terms of the deal were not disclosed. In July … [Read more...] about Yuhan to commercialize Glenmark’s Ryaltris nasal spray in South Korea

Evoke Pharma said that it has signed a deal with Novos Growth Partners (NGP) for commercialization of its Gimoti metoclopramide nasal spray for the treatment of acute and recurrent diabetic gastroparesis in adult women. Evoke's NDA for Gimoti was submitted in June 2018, and the FDA set a PDUFA date of April 1, 2019 for completion of its review. According to Evoke, … [Read more...] about Evoke Pharma partners with Novus Growth Partners for commercialization of Gimoti nasal spray

Senzer has announced that its breath-activated Systemic inhaled Delivery Device (SiDD) inhaler has won a 2018 Good Design award in the medical category. The Good Design Awards are presented by The Chicago Athenaeum: Museum of Architecture and Design "for the most innovative and cutting-edge industrial, product, and graphiτc designs produced around the world." In … [Read more...] about Senzer’s SiDD inhaler wins Good Design Award

According to a report in Israeli financial newspaper Globes, Tel Aviv-based Syqe Medical has raised $50 million in a financing round led by Shavit Capital for continued development of its medicinal plants inhaler. Shavit Capital has posted the news report on its website. The Syqe inhaler delivers metered doses using heat and a controlled flow of air through … [Read more...] about Syqe Medical raises $50 million for inhaler development